Engchem Life Sciences Obtains Domestic Patent for 'EC-18' Applied Diabetes Treatment Substance
[Asia Economy Reporter Chunhee Lee] Engchem Life Sciences has obtained a domestic patent for a diabetes treatment substance applying the new drug development material 'EC-18 (Modedipimod)'.
Engchem Life Sciences is currently developing EC-18, a lipid-based new drug. The company explained that EC-18 protects beta cells in acute diabetes caused by drug-induced beta cell destruction, thereby enhancing therapeutic efficacy.
Diabetes is divided into type 1 and type 2. Among them, EC-18 is used as a treatment for type 1 diabetes, an 'insulin-dependent diabetes' caused by insufficient insulin production in the body.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "To Get Revenge on Ex-Girlfriend" US McDonald's Manager Spits on French Fries
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
An Engchem Life Sciences official stated, "We have completed PCT international application and US patent application, and the examination is currently underway," adding, "It is expected that global pharmaceutical companies will accelerate technology licensing negotiations through obtaining overseas patents."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
